Long-term clinical studies of varicella vaccine at a regional hospital in Japan and proposal for a varicella vaccination program

Vaccine

Volumn 31, Issue 51, 2013, Pages 6155-6160

  Ozaki, Takao ^a  

^a Aichi Prefectural Welfare Federation of Agriculture Co operative Associations Konan Kosei Hospital   (Japan)

Author keywords

Efficacy; Immunogenicity; Routine vaccination program; Safety; Two dose schedule; Varicella vaccine

Indexed keywords

ACICLOVIR; CHICKENPOX VACCINE; VALACICLOVIR;

ANAPHYLAXIS; ANTIBODY RESPONSE; ANTIBODY TITER; CHICKENPOX; CHILD HOSPITALIZATION; CHILDHOOD DISEASE; CLINICAL STUDY; COST BENEFIT ANALYSIS; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; HEMAGGLUTINATION TEST; HIGH RISK POPULATION; HOSPITAL; HOSPITALIZATION COST; HUMAN; IMMUNE ADHERENCE; IMMUNE ADHERENCE HEMAGGLUTINATION TEST; IMMUNOGENICITY; INJECTION SITE SWELLING; JAPAN; LONG TERM CARE; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; SENSITIVITY ANALYSIS; SEROCONVERSION; SERODIAGNOSIS; SHOCK; SINGLE DRUG DOSE; URTICARIA; VACCINATION;

EFFICACY; IMMUNOGENICITY; ROUTINE VACCINATION PROGRAM; SAFETY; TWO-DOSE SCHEDULE; VARICELLA VACCINE;

ANTIBODIES, VIRAL; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; HOSPITALS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOASSAY; INFANT; JAPAN; VACCINATION; VACCINES, ATTENUATED;

EID: 84888428460     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.060     Document Type: Review

References (35)

1. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T., Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2:1288-1290.
2. WHO experts committee on biological standardization Requirements for varicella vaccine (live). Requirements for biological substances No. 36 1985, 102-133. WHO, Geneva.
3. Asano Y., Yazaki T., Miyata T., Nakayama H., Hirose S. Application of a live attenuated varicella vaccine to hospitalized children and its protective effect on spread of varicella infection. Biken J 1975, 18:35-40.
4. Hattori A., Ihara T., Iwasa T., Kamiya H., Sakurai M., Izawa T., et al. Use of live varicella vaccine in children with acute leukaemia or other malignancies. Lancet 1976, 2:210.
5. Ozaki T., Nagayoshi S., Morishima T., Isomura S., Suzuki S., Asano Y., et al. Use of a live varicella vaccine for acute leukemic children shortly after exposure in a children's ward. Biken J 1978, 21:69-72.
6. Katsushima N., Yazaki N., Sakamoto M., Fujiyama J., Nakagawa M., Okuyama Y., et al. Application of a live varicella vaccine to hospitalized children and its follow-up study. Biken J 1982, 25:29-42.
7. Kamiya H., Kato T., Isaji M., Torigoe S., Oitani K., Ito M., et al. Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J 1984, 27:99-102.
8. Ozaki T., Matsui T., Ichikawa T., Asano Y., Yamanishi K., Takahashi M. Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken J 1984, 27:39-42.
9. Ozaki T., Nishimura N., Kajita Y. Experience with live attenuated varicella vaccine (Oka strain) in healthy Japanese subjects; 10-year survey at pediatric clinic. Vaccine 2000, 18:2375-2380.
10. Ozaki T., Nishimura N., Muto T., Sugata K., Kawabe S., Goto K., et al. Safety and immunogenicity of gelatin-free varicella vaccine in epidemiological and serological studies in Japan. Vaccine 2005, 23:1205-1208.
11. Ozaki T. Varicella vaccine. Clin Virol 2010, 38:400-408. Japanese.
12. Kumagai T., Yamanaka T., Wataya Y., Umetsu A., Kawamura N., Ikeda K., et al. Gelatin-specific humoral and cellular immune responses in children with immediate- and nonimmediate-type reactions to live measles, mumps, rubella, and varicella vaccines. J Allergy Clin Immunol 1997, 100:130-134.
13. Kumagai T., Ozaki T., Kamada M., Igarashi C., Yuri K., Furukawa H., et al. Gelatin-containing diphtheria-tetanus-pertussis (DTP) vaccine causes sensitization to gelatin in the recipients. Vaccine 2000, 18:1555-1561.
14. Ozaki T., Nishimura N., Gotoh K., Kawabe S., Funahashi K., Shiraki K., et al. Utility of immune adherence hemagglutination method for antibody measurement of varicella vaccination. Kansenshogaku Zasshi 2012, 86:146-148. Japanese.
15. Ozaki T., Nagai H., Kimura T., Ichikawa T., Suzuki S., Kito H., et al. The age distribution of neutralizing antibodies against varicella-zoster virus in healthy individuals. Biken J 1980, 23:9-14.
16. Kamiya H., Asano Y., Ozaki T., Baba K., Kumagai T., Nagai T., et al. Varicella vaccine potency and stability during transport and delivery. Kansenshogaku Zasshi 2011, 85:161-165. Japanese.
17. Ozaki T., Nishimura N., Gotoh K., Funahashi K. A study for the necessity of virus titer of varicella vaccine presently used. Kansenshogaku Zasshi 2012, 86:749-754. Japanese.
18. Asano Y. Varicella vaccine: the Japanese experience. J Infect Dis 1996, 174(Suppl. 3):S310-S313.
19. Takayama N., Minamitani M., Takayama M. High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatr Jpn 1997, 39:663-668.
20. Izurieta H.S., Strebel P.M., Blake P.A. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care center. J Am Med Assoc 1997, 278:1495-1499.
21. Clements D.A., Moreira S.P., Coplan P.M., Bland C.L., Walter E.B. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatr Infect Dis J 1999, 18:1047-1050.
22. Vázquez M., LaRussa P.S., Gershon A.A., Steinberg S.P., Freudigman K., Shapiro E.D. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001, 344:955-960.
23. Galil K., Fair E., Mountcastle N., Britz P., Seward J. Younger age at vaccination may increase risk of varicella vaccine failure. J Infect Dis 2002, 186:102-105.
24. Dworkin M.S., Jennings C.E., Roth-Thomas J., Lang J.E., Stukenberg C., Lumpkin J.R. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin Infect Dis 2002, 35:102-104.
25. Ozaki T., Morishima T., Hirota T., Sugiyama K., Asano Y. Pediatric admission for vaccine preventable diseases: a 5-year survey from 1994 to 1998 in Aichi Prefecture. Jpn J Infect Dis 1999, 52:208-213.
26. Sugawara T., Ohkusa Y., Oikawa K., Haneda N., Kikuchi K., Kato F., et al. Cost-effectiveness analysis of routine immunization for varicella in Japan. Kansenshogaku Zasshi 2006, 80:212-219. Japanese.
27. CDC National and state vaccination coverage among children aged 19-35 months - United States, 2010. Morb Mortal Wkly Rep 2011, 60:1157-1163.
28. National Institute of Infectious Diseases Fact sheet about varicella vaccine. July 7 2010, 7-8. http://www.mhlw.go.jp/stf/shingi/2r9852000000bx23-att/2r9852000000bxqx.pdf [accessed 15.10.13, in Japanese].
29. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007, 356:1121-1129.
30. Ozaki T., Nishimura N., Gotoh K., Funahashi K., Yoshii H., Okuno Yoshinobu O. Immunogenicity of additional varicella vaccination 3-5 years after the initial vaccination. Kansenshogaku Zasshi 2013, 87:409-414. Japanese.
31. Gao Z., Gidding H.F., Wood J.G., MacIntyre C.R. Modelling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiol Infect 2010, 138:457-468.
32. Shapiro E.D., Vazquez M., Esposito D., Holabird N., Steinberg S.P., Dziura J., et al. Effectiveness of 2 doses of varicella vaccine in children. J Infect Dis 2011, 203:312-315.
33. Kattan J.A., Sosa L.E., Bohnwagner H.D., Hadler J.L. Impact of 2-dose vaccination on varicella epidemiology: Connecticut - 2005-2008. J Infect Dis 2011, 203:509-512.
34. Ohashi M., Kawamura Y., Asano Y., Matsumoto Y., Kato T., Nishimura N., et al. Efficacy and safety of co-administration of live attenuated varicella vaccine and measles-rubella (MR) vaccine. J Jpn Pediatr Soc 2013, 117:1416-1423. Japanese.
35. Fine P.E.M., Mulholland K. Community immunity. Vaccines 2013, 1395-1412. Elsevier, Amsterdam. 6th ed. S.A. Plotkin, W.A. Orenstein, P.A. Offit (Eds.).